Zirabev Injection, Solution
Product Images NDC 0069-0342

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Zirabev (NDC 0069-0342). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Zirabev 01)

A Kaplan-Meier survival curve graph comparing overall survival proportions over a 30-month period for patients treated with IFL plus placebo versus IFL plus bevacizumab. The x-axis represents duration of survival in months, and the y-axis shows the proportion surviving. The graph includes a table indicating the number of patients at risk at specified time points for each treatment group.*

FDA Label Image

Figure 2 (Zirabev 02)

A Kaplan-Meier survival curve chart showing the proportion of patients surviving over study months up to 48 months. Two treatment groups are compared: chemotherapy alone (dashed line) and chemotherapy plus bevacizumab (solid line). A table below the graph provides the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 3 (Zirabev 03)

A Kaplan-Meier survival curve comparing the proportion of patients surviving over months for two groups: PC alone (n=444) and PC plus bevacizumab (n=434). The x-axis shows duration of survival up to 50 months, and the y-axis shows the proportion surviving from 0 to 1. A table below the graph indicates the number of patients at risk at various time points for each group.*

FDA Label Image

Figure 4 (Zirabev 04)

A Kaplan-Meier curve comparing progression-free survival over 24 months between patients treated with bevacizumab plus IFN-alfa and those treated with placebo plus IFN-alfa. The y-axis represents the proportion of patients progression free, and the x-axis shows time in months. Number of patients at risk at various intervals is listed below the graph for both groups.*

FDA Label Image

Figure 5 (Zirabev 05)

A Kaplan-Meier survival curve graph showing the proportion of overall survival over time in months for two groups: chemotherapy alone and chemotherapy plus bevacizumab. The graph includes survival curves with confidence intervals and a table of numbers at risk at various time points for each group.*

FDA Label Image

Figure 6 (Zirabev 06)

A Kaplan-Meier curve chart depicting progression-free survival over months for three patient groups labeled CPP, CPB15, and CPB15+, with corresponding sample sizes. The y-axis represents the proportion progression-free, and the x-axis shows time in months, accompanied by a risk table indicating patient counts at various time points.*

FDA Label Image

Figure 7 (Zirabev 07)

A Kaplan-Meier curve showing the proportion of progression-free survival over time in months. Two groups, labeled CT (n=182) and CT+BV (n=179), are compared for progression-free survival duration up to 24 months. The chart includes a number-at-risk table for each group at various time points along the x-axis.*

FDA Label Image

Figure 8 (Zirabev 08)

A survival curve chart showing the proportion of patients progression free over time since randomization (months). Two treatment groups are compared: CG+PI (dashed line) and CG+Bv (solid line), with the CG+Bv group maintaining a higher proportion progression free over time up to 30 months. The chart includes numeric data at specific time points below the x-axis.*

FDA Label Image

Figure 9 (Zirabev 09)

A Kaplan-Meier survival curve chart showing the proportion surviving over study months for two randomized treatment groups: Crb+Pac (solid line) and Crb+Pac+Bev (dashed line). The x-axis represents study months, while the y-axis shows the proportion surviving. Number of patients at risk at various months is indicated below for each group.*

FDA Label Image

Logo (Zirabev 10)

FDA Label Image

Principal Display Panel (4 mL Vial Label)

Zirabev 100 mg/4 mL injection solution label showing the generic name bevacizumab-bvzr. The label indicates it is for intravenous infusion after dilution, a single-dose vial with no preservative. Storage instructions specify refrigeration at 2°C to 8°C and protection from light. The labeler is Pfizer Inc, New York.*

FDA Label Image

Principal Display Panel (4 mL Vial Carton)

Zirabev 100 mg/4 mL (25 mg/mL) injection carton label for single-dose vial. This intravenous infusion solution label shows dosage instructions, storage conditions, and that it contains bevacizumab-bvzr. The labeler is Pfizer Laboratories Div Pfizer Inc. The carton highlights discarding unused portions and includes a barcode and manufacturing details.*

FDA Label Image

Principal Display Panel (16 mL Vial Label)

Zirabev 400 mg/16 mL (bevacizumab-bvzr) injection solution label for intravenous infusion. The label indicates a single-dose vial with a concentration of 25 mg/mL and includes storage instructions to keep refrigerated at 2°C to 8°C (36°F to 46°F), protect from light, and not to freeze or shake. Manufactured by Pfizer Laboratories Div Pfizer Inc.*

FDA Label Image

Principal Display Panel (16 mL Vial Carton)

Label for Zirabev 400 mg/16 mL (25 mg/mL) injection solution for intravenous infusion after dilution. The carton contains one single-dose vial. The label includes dosage strength, administration instructions, storage conditions, and manufacturer information, Pfizer Inc. Warnings to discard unused portion and no preservative presence are noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.